Nicolas Whenham

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2019 · 180 citations · Full text

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

Emmanuel Seront, Sylvie Rottey, Brieuc Sautois et al. · Annals of Oncology · 2012 · 124 citations · Full text

Urology, Genitourinary Cancer, Medicine +7

Long-term survival after glioblastoma resection: hope despite poor prognosis factors

Emmanuel Costa, Tévi Morel Lawson, Julie Lelotte et al. · Journal of Neurosurgical Sciences · 2019 · 23 citations

Health-related quality of life and cognitive failures in patients with lower-grade gliomas treated with radiotherapy

Dario Di Perri, S. Jmil, Tévi Morel Lawson et al. · Cancer/Radiothérapie · 2023 · 23 citations

Quality Of Life, Neuro-oncology, Life Assessment +11

Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial

Ahmad Awada, Thierry Gil, Nicolas Whenham et al. · The Journal of Clinical Pharmacology · 2011 · 20 citations

Oncology, Sorafenib Combined, Mg Bid Sorafenib +10